Tirzepatide Induces Rapid Remission in Severe Hailey-Hailey Disease

Hailey-Hailey disease (HHD), also known as familial benign chronic pemphigus, is a rare, inherited autosomal dominant skin disorder characterized by recurrent, painful blisters, erosions, and maceration, primarily affecting intertriginous areas like the armpits, groin, and neck. This debilitating condition significantly impairs quality of life due to chronic pain, odor, and susceptibility to secondary infections. It stems from a genetic mutation in the ATP2C1 gene, which encodes a calcium-manganese ATPase pump crucial for proper keratinocyte (skin cell) adhesion and differentiation. Current therapeutic options for HHD are largely symptomatic, including topical corticosteroids, antibiotics, and retinoids, with limited long-term efficacy and significant side effects, leaving many patients with refractory disease. There is a critical unmet need for novel, disease-modifying treatments that can induce sustained remission and improve patient outcomes in HHD.